Crispr Therapeutics AG (CRSP) stock saw a modest uptick, ending the day at $40.49 which represents a slight increase of $0.49 or 1.23% from the prior close of $40. The stock opened at $40 and touched ...

Stem cell engineering and CRISPR were used to create mice with two male parents. Could we use this technique on humans?

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have ...

By treating DNA as a language, Brian Hie’s “ChatGPT for genomes” could pick up patterns that humans can’t see, accelerating ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new approach to treating cancer that uses engineered fat cells to deprive tumors ...

Study reveals the impact of X chromosome on brain aging in women. Learn how maternal and paternal X chromosome can influence ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.72%. On the ...

In a shift away from GMOS, aka genetically modified organisms, important research is continuing in gene editing, sometimes ...

Polo Pureza, whose name translates from Spanish as "Polo Purity," was inducted into the Argentine Association of Polo Horse ...